<DOC>
	<DOCNO>NCT00274703</DOCNO>
	<brief_summary>Eosinophils play key role pathogenesis eosinophilic oesophagitis . Therapies suppress eosinophil recruitment activation may give benefit . Mepolizumab humanise monoclonal antibody interleukin-5 ( IL-5 ) . This study evaluate ability mepolizumab decrease recruitment infiltration eosinophils oesophagus , thereby reduce inflammation symptom EE ( eosinophilic oesophagitis ) adult patient .</brief_summary>
	<brief_title>An Evaluation Of Mepolizumab In Therapy Of Eosinophilic Oesophagitis In Adult Patients</brief_title>
	<detailed_description />
	<mesh_term>Esophagitis</mesh_term>
	<mesh_term>Eosinophilic Esophagitis</mesh_term>
	<criteria>Document evidence/presence Oesophagitis prior commence trial drug . ) Histological evidence Oesophagitis : great 20x eosinophil per high power field ( X400 ) histology esophageal mucosal biopsy b. least one episode dysphagia per week c.Inadequate response routine EE treatment D. No known cause oesophagitis , esophageal generalize eosinophilia Not pregnant nursing Exclusion criterion : History seasonal worsening EE symptom requirement Esophageal dilation . ChurgStrauss Syndrome Wegener 's Granulomatosis Lymphoma , hematological malignancy , advance metastatic solid tumor Active H. pylori infection . Any previous treatment antihIL5 , antiIgE monoclonal antibody biological agent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>anti IL-5</keyword>
	<keyword>oesophagitis</keyword>
	<keyword>eosinophil</keyword>
	<keyword>mepolizumab</keyword>
	<keyword>adult</keyword>
</DOC>